- Home
- PCRX vs GIII Comparison
PCRX vs GIII Comparison
Compare PCRX & GIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- GIII
- Stock Information
- Founded
- PCRX 2006
- GIII 1956
- Country
- PCRX United States
- GIII United States
- Employees
- PCRX N/A
- GIII N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- GIII Apparel
- Sector
- PCRX Health Care
- GIII Consumer Discretionary
- Exchange
- PCRX Nasdaq
- GIII Nasdaq
- Market Cap
- PCRX 1.2B
- GIII 1.0B
- IPO Year
- PCRX 2011
- GIII 1989
- Fundamental
- Price
- PCRX $22.07
- GIII $23.25
- Analyst Decision
- PCRX Buy
- GIII Buy
- Analyst Count
- PCRX 8
- GIII 6
- Target Price
- PCRX $28.38
- GIII $28.83
- AVG Volume (30 Days)
- PCRX 590.9K
- GIII 605.6K
- Earning Date
- PCRX 08-05-2025
- GIII 09-04-2025
- Dividend Yield
- PCRX N/A
- GIII N/A
- EPS Growth
- PCRX N/A
- GIII 12.17
- EPS
- PCRX N/A
- GIII 4.28
- Revenue
- PCRX $702,772,000.00
- GIII $3,154,658,000.00
- Revenue This Year
- PCRX $7.90
- GIII $0.32
- Revenue Next Year
- PCRX $11.02
- GIII N/A
- P/E Ratio
- PCRX N/A
- GIII $5.44
- Revenue Growth
- PCRX 3.08
- GIII 1.72
- 52 Week Low
- PCRX $11.16
- GIII $20.33
- 52 Week High
- PCRX $27.64
- GIII $36.18
- Technical
- Relative Strength Index (RSI)
- PCRX 44.39
- GIII 45.32
- Support Level
- PCRX $20.85
- GIII $23.40
- Resistance Level
- PCRX $22.32
- GIII $24.59
- Average True Range (ATR)
- PCRX 0.84
- GIII 0.71
- MACD
- PCRX 0.01
- GIII 0.02
- Stochastic Oscillator
- PCRX 44.69
- GIII 20.24
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About GIII G-III Apparel Group LTD.
G-III Apparel Group Ltd is a textile company. It makes a wide range of apparel, footwear, and accessories that it sells under its own brands, licensed brands, and private-label brands. G-III has a substantial portfolio for licensed and proprietary brands, anchored by five global power brands: DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger, and Karl Lagerfeld. The company has two reportable operations: Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, as well as sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenues from Wholesale operations.